Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1187mxw

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	DEC 23	New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/ USPAT2
NEWS 4	JAN 13	IPC 8 searching in IFIPAT, IFIUDB, and IFICDB
NEWS 5	JAN 13	New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to INPADOC
NEWS 6	JAN 17	Pre-1988 INPI data added to MARPAT
NEWS 7	JAN 17	IPC 8 in the WPI family of databases including WPIFV
NEWS 8	JAN 30	Saved answer limit increased
NEWS 9	FEB 21	STN AnaVist, Version 1.1, lets you share your STN AnaVist visualization results
NEWS 10	FEB 22	The IPC thesaurus added to additional patent databases on STN
NEWS 11	FEB 22	Updates in EPFULL; IPC 8 enhancements added
NEWS 12	FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS 13	FEB 28	MEDLINE/LMEDLINE reload improves functionality
NEWS 14	FEB 28	TOXCENTER reloaded with enhancements
NEWS 15	FEB 28	REGISTRY/ZREGISTRY enhanced with more experimental spectral property data
NEWS 16	MAR 01	INSPEC reloaded and enhanced
NEWS 17	MAR 03	Updates in PATDPA; addition of IPC 8 data without attributes
NEWS 18	MAR 08	X.25 communication option no longer available after June 2006
NEWS 19	MAR 22	EMBASE is now updated on a daily basis
NEWS 20	APR 03	New IPC 8 fields and IPC thesaurus added to PATDPAFULL
NEWS 21	APR 03	Bibliographic data updates resume; new IPC 8 fields and IPC thesaurus added in PCTFULL
NEWS 22	APR 04	STN AnaVist $500 visualization usage credit offered
NEWS 23	APR 12	LINSPEC, learning database for INSPEC, reloaded and enhanced
NEWS 24	APR 12	Improved structure highlighting in FQHIT and QHIT display in MARPAT
NEWS 25	APR 12	Derwent World Patents Index to be reloaded and enhanced during second quarter; strategies may be affected
NEWS 26	MAY 10	CA/CAplus enhanced with 1900-1906 U.S. patent records

NEWS EXPRESS FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.
V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT
http://download.cas.org/express/v8.0-Discover/

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer

agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* *

COMPLETE THE STN SURVEY - APRIL 27 THROUGH MAY 31

Dear valued STN customer,

In an effort to enhance your experience with STN, we would like to better understand what you find useful. Please take approximately 5 minutes to complete a web survey.

If you provide us with your name, login ID, and e-mail address, you will be entered in a drawing to win a free iPod(R). Your responses will be kept confidential and will help us make future improvements to STN.

Take survey: http://www.zoomerang.com/survey.zgi?p=WEB2259HNKWTUW

Thank you in advance for your participation.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 15:17:55 ON 10 MAY 2006

=> file ca

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'CA' ENTERED AT 15:18:02 ON 10 MAY 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 4 May 2006 VOL 144 ISS 20
FILE LAST UPDATED: 4 May 2006 (20060504/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> amplodine
AMPLODINE IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter "HELP COMMANDS" at an arrow prompt (=>).

```
=> s amplodine
L1            0 AMPLODINE

=> s amlodipine
L2         2041 AMLODIPINE

=> s crystal? and l2
       1675494 CRYSTAL?
L3           40 CRYSTAL? AND L2

=> d ti 1-10

L3   ANSWER 1 OF 40  CA  COPYRIGHT 2006 ACS on STN
TI   Process for the preparation of pure amlodipine

L3   ANSWER 2 OF 40  CA  COPYRIGHT 2006 ACS on STN
TI   Combinations comprising (S)-amlodipine and a cholesteryl ester
     transfer protein inhibitor, and methods for reducing hypertension

L3   ANSWER 3 OF 40  CA  COPYRIGHT 2006 ACS on STN
TI   Saccharin Salts of Active Pharmaceutical Ingredients, Their
     Crystal Structures, and Increased Water Solubilities

L3   ANSWER 4 OF 40  CA  COPYRIGHT 2006 ACS on STN
TI   Combinations comprising (S)-amlodipine and an HMG-CoA reductase
     inhibitor and/or cholesterol absorption inhibitor for reducing
     hypertension

L3   ANSWER 5 OF 40  CA  COPYRIGHT 2006 ACS on STN
TI   Preparation of (S)-amlodipine malate for pharmaceuticals

L3   ANSWER 6 OF 40  CA  COPYRIGHT 2006 ACS on STN
TI   Combination of (S)-amlodipine and an ACE inhibitor for reducing
     hypertension

L3   ANSWER 7 OF 40  CA  COPYRIGHT 2006 ACS on STN
TI   Multiparticulate crystalline drug compositions containing a
     Poloxamer and a glyceride

L3   ANSWER 8 OF 40  CA  COPYRIGHT 2006 ACS on STN
TI   Phthaloyl amlodipine

L3   ANSWER 9 OF 40  CA  COPYRIGHT 2006 ACS on STN
TI   Process for preparing amlodipine mesylate monohydrate

L3   ANSWER 10 OF 40  CA  COPYRIGHT 2006 ACS on STN
TI   Process for preparing stable amorphous amlodipine camsylate and
     pharmaceutical dosage formulations for its oral administration


=> d ab

L3   ANSWER 1 OF 40  CA  COPYRIGHT 2006 ACS on STN
AB   The invention relates to an improved process for the preparation of pure
     amlodipine (I) via the effective purification of phthalimidoamlodipine
     (II). Cyclocondensation of 2-chlorobenzaldehyde, Me 3-aminocrotonate, and
     Et 4-[2-(phthalimido)ethoxy]acetoacetate gave compound II, in 32% yield. II
     is dissolved in a halogenated hydrocarbon, such as dichloromethane, and
     insol. impurities removed by filtration. Gradual addition of an aliphatic
     hydrocarbon, such as n-hexane, results in the crystallization of II in 87%
yield.
     The phthaloyl group is removed with methylamine in ethanol, and pure
     amlodipine free base is isolated, in 87% yield, by precipitation from the
     reaction mixture by quenching with hot water. The volume of the halogenated
```

solvent is about 1 volume to 6 vols. with respect to II and the volume of the aliphatic solvent is 1 volume to 12 vols. with respect to II. The hot water temperature is between 45 °C and 65 °C. The process gives **amlodipine** with high purity without the use of extensive work-up procedures.

=> d

L3 ANSWER 1 OF 40 CA COPYRIGHT 2006 ACS on STN
AN 144:128856 CA
TI Process for the preparation of pure **amlodipine**
IN Chava, Satyanarayana; Ramanjaneyulu, Gorantla Seeta; Rao, Konudula Babu
PA Matrix Laboratories Ltd, India
SO PCT Int. Appl., 12 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006003672	A1	20060112	WO 2004-IN195	20040702

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRAI WO 2004-IN195 20040702
RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d ti 11-20

L3 ANSWER 11 OF 40 CA COPYRIGHT 2006 ACS on STN
TI A process for the preparation of **amlodipine** and its salts

L3 ANSWER 12 OF 40 CA COPYRIGHT 2006 ACS on STN
TI Method of preparation of **amlodipine** benzenesulfonate

L3 ANSWER 13 OF 40 CA COPYRIGHT 2006 ACS on STN
TI Preparation of **crystalline amlodipine** maleate

L3 ANSWER 14 OF 40 CA COPYRIGHT 2006 ACS on STN
TI A process for the preparation of (S)-(-)-**amlodipine** nicotinate and its hydrates as antihypertensive agents with improved activity and photostability

L3 ANSWER 15 OF 40 CA COPYRIGHT 2006 ACS on STN
TI **Crystalline** adipic acid salt of **amlodipine**

L3 ANSWER 16 OF 40 CA COPYRIGHT 2006 ACS on STN
TI Two **crystalline** hydrate forms of **amlodipine** benzenesulfonate of high purity, processes for their preparation and use

L3 ANSWER 17 OF 40 CA COPYRIGHT 2006 ACS on STN
TI Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of cardiovascular disorders

L3 ANSWER 18 OF 40 CA COPYRIGHT 2006 ACS on STN
TI Process for the preparation of [S(-)**amlodipine** -L(+)-hemitartarate]

L3 ANSWER 19 OF 40 CA COPYRIGHT 2006 ACS on STN
TI Solid oral dosage forms containing **amlodipine** free base

L3 ANSWER 20 OF 40 CA COPYRIGHT 2006 ACS on STN
TI Methods for the treatment or prophylaxis of aldosterone-mediated pathogenic effects in a subject using an epoxy-steroidal aldosterone antagonist

=> d ab 11

L3 ANSWER 11 OF 40 CA COPYRIGHT 2006 ACS on STN
AB The title compound (I) is isolated in pure form by using a crystallization process
and converted to its pharmaceutically acceptable salts. The crystallization process affects stability and purity of the **amlodipine** salts. All known impurities and one unknown impurity, which forms during the synthesis of the **amlodipine** salts, were isolated, characterized, and synthesized. A new method allowing the quant. HPLC anal. of all related impurities of **amlodipine** salts in a single chromatogram was developed.

=> d 11

L3 ANSWER 11 OF 40 CA COPYRIGHT 2006 ACS on STN
AN 141:123565 CA
TI A process for the preparation of **amlodipine** and its salts
IN Aslan, Tuncer; Adiyaman, Mustafa; Yurdakul, Aycil; Sahpaz, Filiz; Ozarslan, Evren A.; Guner, Didem; Ridvanoglu, Nurten
PA Eos Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ticaret A.S., Turk.
SO PCT Int. Appl., 34 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004058711	A1	20040715	WO 2002-TR78	20021230
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002368531	A1	20040722	AU 2002-368531	20021230
PRAI WO 2002-TR78	A	20021230		

OS CASREACT 141:123565

=> d 19

L3 ANSWER 19 OF 40 CA COPYRIGHT 2006 ACS on STN
AN 139:185682 CA
TI Solid oral dosage forms containing **amlodipine** free base

IN Peters, Theodorus Hendricus Antonius; Benneker, Franciscus Bernardus Gemma; Lemmens, Jacobus Maria; Keltjens, Rolf
PA Synthon Licensing, Ltd., Luxembourg
SO Brit. UK Pat. Appl., 35 pp.
CODEN: BAXXDU
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	GB 2385268	A1	20030820	GB 2002-2536	20020204
	SI 21121	C	20030831	SI 2002-28	20020205
	ZA 2002001080	A	20020913	ZA 2002-1080	20020207
	BE 1014922	A3	20040601	BE 2002-140	20020301
PRAI	GB 2002-2536	A	20020204		

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d ab 19

L3 ANSWER 19 OF 40 CA COPYRIGHT 2006 ACS on STN
AB **Amlodipine** free base can be formulated into a convenient oral dosage form, especially a tablet, without excessive stickiness or tablet punch residue. The **amlodipine** free base can be crystalline Form 1 or a novel Form II. Methods of making and using the **amlodipine** free base are disclosed. Thus, **amlodipine** besylate was dissolved in 2-PrOH and treated with 1M NaOH solution to give the free base. Tbalts contained **amlodipine** 2.5, calcium hydrogen phosphate 315, microcryst. cellulose 62.05, sodium starch glycolate 2.0, and Mg stearate 1.0 mg.

=> d ti 21-30

L3 ANSWER 21 OF 40 CA COPYRIGHT 2006 ACS on STN
TI Pharmaceutical compositions containing AT1-receptor antagonists

L3 ANSWER 22 OF 40 CA COPYRIGHT 2006 ACS on STN
TI Physico-chemical Characterization of Hydrated and Anhydrous **Crystal** Forms of **Amlodipine** Besylate

L3 ANSWER 23 OF 40 CA COPYRIGHT 2006 ACS on STN
TI A **crystalline** form of the free base of **amlodipine**

L3 ANSWER 24 OF 40 CA COPYRIGHT 2006 ACS on STN
TI Porous drug matrices and methods of manufacture thereof

L3 ANSWER 25 OF 40 CA COPYRIGHT 2006 ACS on STN
TI Preparation of **amlodipine** hemimaleate

L3 ANSWER 26 OF 40 CA COPYRIGHT 2006 ACS on STN
TI Preparation of free **amlodipine** base and its usage for tablets

L3 ANSWER 27 OF 40 CA COPYRIGHT 2006 ACS on STN
TI **Amlodipine** mesylate salts and their preparation

L3 ANSWER 28 OF 40 CA COPYRIGHT 2006 ACS on STN
TI Preparation of **amlodipine** hemimaleate

L3 ANSWER 29 OF 40 CA COPYRIGHT 2006 ACS on STN
TI Process for making **amlodipine** maleate

L3 ANSWER 30 OF 40 CA COPYRIGHT 2006 ACS on STN

TI Preparation of **amlodipine** hemifumarate and usage in pharmaceutical formulations

=> d 23

L3 ANSWER 23 OF 40 CA COPYRIGHT 2006 ACS on STN
AN 138:193310 CA
TI A **crystalline** form of the free base of **amlodipine**
IN Bentham, Alan Craig; Pettman, Alan John; Ruddock, Keith Stephen
PA Pfizer Limited, UK; Pfizer Inc.
SO Eur. Pat. Appl., 11 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 1287826	A1	20030305	EP 2002-255716	20020815
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2003128653	A2	20030508	JP 2002-235998	20020813
US 2003119883	A1	20030626	US 2002-224663	20020820
US 6680334	B2	20040120		
CA 2399567	AA	20030228	CA 2002-2399567	20020823
BR 2002003412	A	20030527	BR 2002-3412	20020828
PRAI GB 2001-20808	A	20010828		
US 2001-327155P	P	20011003		

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d ab 23

L3 ANSWER 23 OF 40 CA COPYRIGHT 2006 ACS on STN
AB The present invention relates to **amlodipine** free base in a crystalline form, to pharmaceutical formulations comprising such material, processes of manufacture and its use in therapy. Thus, **amlodipine** besylate was dissolved in CH2Cl2/water (1:1) and the emulsion was made alkaline to pH 11 with 5M aqueous NaOH to give the free base. The free base was crystallized from toluene and a tablet formulation was prepared by using 1.00 g **amlodipine**.

=> d 26

L3 ANSWER 26 OF 40 CA COPYRIGHT 2006 ACS on STN
AN 137:159339 CA
TI Preparation of free **amlodipine** base and its usage for tablets
PA Bioorganics B.V., Neth.
SO Ger. Gebrauchsmusterschrift, 41 pp.
CODEN: GGXXFR
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI DE 20201878	U1	20020814	DE 2002-20201878	20020207
PRAI DE 2002-20201878		20020207		

=> d ab 26

L3 ANSWER 26 OF 40 CA COPYRIGHT 2006 ACS on STN
AB The invention concerns the preparation of **amlodipine** from phthalodipine using aqueous methylamine, recrystn. of the product to **crystal** forms I or II, and pressing the drug substance into tablets with calcium phosphate and microcryst. cellulose. The compns. do not stick to the temp during tablet pressing. Thus 250 mL 40% methylamine and 31.5 g phthalodipine were mixed at 40-45 °C for 16 h; 460 mL toluene were added for extraction; the organic phase was evaporated until dryness, 21.6 g **amlodipine** were obtained. **Amlodipine** was recrystd. in ethanol and used for tabletting for a composition (mg): **amlodipine** 2.5; calcium hydrogen phosphate, hydrate-free 31.5; microcryst. cellulose 62.05; sodium starch glycolate 2.0; magnesium stearate 1.0.

=> d ti 31-40

L3 ANSWER 31 OF 40 CA COPYRIGHT 2006 ACS on STN
TI Synergistic effect of **amlodipine** and atorvastatin

L3 ANSWER 32 OF 40 CA COPYRIGHT 2006 ACS on STN
TI Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure and other cardiovascular disorders

L3 ANSWER 33 OF 40 CA COPYRIGHT 2006 ACS on STN
TI Preparation of **amlodipine** hemimaleate and usage in pharmaceutical formulations to treat angina and high blood pressure

L3 ANSWER 34 OF 40 CA COPYRIGHT 2006 ACS on STN
TI Methods of determining individual hypersensitivity to a pharmaceutical agent from gene expression profile

L3 ANSWER 35 OF 40 CA COPYRIGHT 2006 ACS on STN
TI Chromatographic investigation on the binding site characteristics of quail egg-white riboflavin binding protein as a chiral stationary phase

L3 ANSWER 36 OF 40 CA COPYRIGHT 2006 ACS on STN
TI Preparation of **amlodipine** benzenesulfonate for pharmaceuticals

L3 ANSWER 37 OF 40 CA COPYRIGHT 2006 ACS on STN
TI Determination of the absolute configuration of the active **amlodipine** enantiomer as (-)-S: a correction

L3 ANSWER 38 OF 40 CA COPYRIGHT 2006 ACS on STN
TI Dihydropyrimidine calcium channel blockers. 4. Basic 3-substituted-4-aryl-1,4-dihydropyrimidine-5-carboxylic acid esters. Potent antihypertensive agents

L3 ANSWER 39 OF 40 CA COPYRIGHT 2006 ACS on STN
TI Comparison of location and binding for the positively charged 1,4-dihydropyridine calcium channel antagonist **amlodipine** with uncharged drugs of this class in cardiac membranes

L3 ANSWER 40 OF 40 CA COPYRIGHT 2006 ACS on STN
TI Long-acting dihydropyridine calcium antagonists. 1. 2-Alkoxymethyl derivatives incorporating basic substituents

=> d 37

L3 ANSWER 37 OF 40 CA COPYRIGHT 2006 ACS on STN
AN 117:171154 CA

TI Determination of the absolute configuration of the active **amlodipine** enantiomer as (-)-S: a correction
AU Goldmann, Siegfried; Stoltefuss, Juergen; Born, Liborius
CS Pharma Res. Cent., Bayer AG, Wuppertal, 5600/1, Germany
SO Journal of Medicinal Chemistry (1992), 35(18), 3341-4
CODEN: JMCMAR; ISSN: 0022-2623
DT Journal
LA English

=> d ab 37

L3 ANSWER 37 OF 40 CA COPYRIGHT 2006 ACS on STN
AB The active (-) enantiomer of **amlodipine** (I) was originally reported to have the R configuration. This does not concur with other 1,4-dihydropyridines with known absolute configuration. This configuration has now been determined by x-ray structural anal. using (1S)-camphanic acid and (S)-2-methoxy-2-phenylethanol as chiral probes. Both detns. gave the S configuration for the **amlodipine** (-) enantiomer with the greater Ca-antagonistic activity.